{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-004143","form_type":"8-K","ticker":"AGIO","cik":"0001439222","company_name":"AGIOS PHARMACEUTICALS, INC.","filed_at":"2023-01-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.005547+00:00","generated_at":"2026-06-20T17:40:01.061773+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Agios unveils 2023-2026 catalysts: PYRUKYND approvals, pipeline expansion, cash-flow positivity by 2026","bullets":["Five ongoing pivotal PYRUKYND trials in thalassemia, sickle cell, and pediatric PK deficiency.","Potential FDA approvals: thalassemia 2025, sickle cell 2026, pediatric PK deficiency 2026.","Expects to complete ENERGIZE/ENERGIZE-T enrollment by mid-2023; RISE UP Phase 2 data and go/no-go by mid-year.","AG-946 Phase 2a enrollment in LR-MDS completed by year-end 2023; IND filing for PAH stabilizer in PKU planned.","Appointed Tsveta Milanova as CCO; EU/Great Britain approval for PYRUKYND in adult PK deficiency already received."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-004143","json":"https://secwatch.observer/filing/0001193125-23-004143.json","markdown":"https://secwatch.observer/filing/0001193125-23-004143.md","text":"https://secwatch.observer/filing/0001193125-23-004143.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1439222/000119312523004143/0001193125-23-004143-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1439222/000119312523004143/d408672d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T17:40:01.061773+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}